MedPage Today

Subcutaneous Ocrelizumab Not Inferior to IV Infusion

MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III ...
Healthline

Ocrelizumab for MS: Is It Right for You?

Ocrelizumab (Ocrevus) is a prescription medication that targets certain B cells in your body’s immune system. The Food and Drug Administration (FDA) has approved ocrelizumab to treat relapse-remitting ...
Nasdaq

FDA and EMA Accept Applications for Genentech’s Ocrevus (ocrelizumab) Shorter 2-hour Infusion Time

– Reduces infusion time to 2 hours from the current 3.5 hours for patients with relapsing or primary progressive multiple sclerosis, if approved – – Applications are based on data from the randomized, ...
Medscape

FDA Approves Shorter Infusion Time for MS Drug Ocrelizumab

The US Food and Drug Administration (FDA) has approved a shorter infusion time for ocrelizumab (Ocrevus) for patients with relapsing or primary progressive multiple sclerosis (MS), the company has ...
Monthly Prescribing Reference

Investigational SC Formulation of Ocrelizumab Noninferior to IV Infusion in MS Trial

Credit: Getty Images. The SC formulation is intended to be administered in 10 minutes twice a year. Positive data were announced from a phase 3 trial evaluating an investigational subcutaneous (SC) ...
Nasdaq

FDA Approves Genentech’s Ocrevus (ocrelizumab) Shorter 2-Hour Infusion for Relapsing and Primary Progressive Multiple Sclerosis

– Approval based on data from the randomized, double-blind ENSEMBLE PLUS study, showing consistent safety to the conventional Ocrevus dosing regimen – – Shorter infusion time will further improve the ...
Healio

‘No new safety concerns’ emerge for ocrelizumab in MS subpopulations

Please provide your email address to receive an email when new articles are posted on . Continuous administration of ocrelizumab in clinical trials and its broader use in real-world settings exhibited ...
FiercePharma

Phase II Study with Ocrelizumab Shows Significant Reduction in Disease Activity for Multiple Sclerosis Patients

GOTHENBURG, Sweden--(BUSINESS WIRE)-- Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (NASDAQ:BIIB) today announced 24-week results 1 from a phase II study ...
Medscape

Does MS Drug Dosing Regimen Need Revising?

The study appeared online Jan. 21 in the journal Multiple Sclerosis and Related Disorders, presented by lead author Mahmoud AbdelRazek, MD, at the annual meeting held by the Americas Committee for ...
FierceBiotech

First Phase III study evaluating Roche's ocrelizumab in patients with rheumatoid arthritis meets primary endpoint

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that STAGE, a Phase III trial evaluating ocrelizumab as a treatment for seropositive* rheumatoid arthritis (RA) patients with a previous inadequate ...
Business Wire

FDA and EMA Accept Applications for Genentech’s Ocrevus (ocrelizumab) Shorter 2-hour Infusion Time

FDA and EMA Accept Applications for Genentech’s Ocrevus (ocrelizumab) Shorter 2-hour Infusion Time – Reduces infusion time to 2 hours from the current 3.5 hours for patients with relapsing or primary ...
Business Wire

FDA Approves Genentech’s Ocrevus (ocrelizumab) Shorter 2-Hour Infusion for Relapsing and Primary Progressive Multiple Sclerosis

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a ...